To study PD-L1 expression dynamics in the context of CART therapy, we examined tumor cells collected at the time of surgical resection from 14 patients with newly diagnosed or recurrent GBM at baseline and after exposure to the T-cell effector cytokine IFN-γ. This evidence concerns the gene IFNG and neoplasm.